DDInter1628 DDInter1059
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Meperidine
Meperidine {u} (Compound) resembles {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Milnacipran
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Milnacipran
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Anagrelide
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Ruxolitinib {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is regulated by {v} (Gene) BID
BID {u} (Gene) is downregulated by {v} (Compound) Levomilnacipran
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levomilnacipran (Compound)
Ruxolitinib (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Levomilnacipran (Compound)
Ruxolitinib (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound)
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Meperidine (Compound) and Meperidine (Compound) resembles Levomilnacipran (Compound)
Ruxolitinib (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Milnacipran (Compound) and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Ruxolitinib (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Milnacipran (Compound) and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Anagrelide (Compound) and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Ruxolitinib (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is regulated by BID (Gene) and BID (Gene) is downregulated by Levomilnacipran (Compound)
Ruxolitinib (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran